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Apolipoprotein E4 (ApoE4) is found in 25% of the 
population, and in 60% of Alzheimer’s disease (AD) 
patients. Cerebral hypometabolism is associated with  
 
decreased memory ability and is believed to be a 
diagnostic biomarker for cognitive impairment at 
preclinical stages of AD [1–5]. Individuals with ApoE4 
have reduced glucose metabolism even in young 
adulthood in specific brain regions [6–11]. Studies also 
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Background: Apolipoprotein E4 (ApoE4) is the major genetic risk factor of Alzheimer’s disease (AD). ApoE4 
carriers have cerebral hypometabolism which is thought as a harbinger of AD.  Our previous studies indicated 
ketones improved mitochondria energy metabolism via sirtuin 3 (Sirt3). However, it is unclear whether ketones 
upregulate Sirt3 and improve ApoE4-related learning and memory deficits. 
Results: Ketones improved learning and memory abilities of ApoE4 mice but not ApoE3 mice. Sirt3, synaptic 
proteins, the NAD+/ NADH ratio, and ATP production were significantly increased in the hippocampus and the 
cortex from ketone treatment. 
Methods: Human ApoE3 and ApoE4 transgenic mice (9-month-old) were treated with either ketones or normal 
saline by daily subcutaneous injections for 3 months (ketones, beta-hydroxybutyrate (BHB): 600 mg/kg/day; 
acetoacetate (ACA): 150 mg/kg/day). Learning and memory ability of these mice were assessed. Sirt3 protein, 
synaptic proteins (PSD95, Synaptophysin), the NAD+/ NADH ratio, and ATP levels were measured in the 
hippocampus and the cortex. 
Conclusion: Our current studies suggest that ketones improve learning and memory abilities of ApoE4 
transgenic mice. Sirt3 may mediate the neuroprotection of ketones by increasing neuronal energy metabolism 
in ApoE4 transgenic mice. This provides the foundation for Sirt3’s potential role in the prevention and 
treatment of AD. 
www.aging-us.com 4580 AGING 
found that ApoE4 was also associated with reduced 
ATP levels in the cerebral cortex in mouse models [12–
15].  
 
Our previous studies found that peripheral 
administration of ketones significantly reduced amyloid 
burden and greatly improved learning and memory 
ability in a symptomatic model of APP transgenic mice 
[16]. Sirt3 was involved in the pathogenesis of AD and 
was downregulated by Aβ [17, 18]. Further studies 
discovered that the Sirt3-related energy pathway played 
a critical role in neuronal hypometabolism [18]. For 
example, Sirt3 mediates the neuroprotective effect of 
ketones in an ischemia mouse model of middle cerebral 
artery occlusion [19]. These findings support the 
concept that ketones are not only metabolites [20, 21], 
but they are also endogenous neuroprotective agents 
[16, 22]. However, it is not fully understood whether 
ketones upregulate Sirt3 and improve learning and 
memory abilities of ApoE4 transgenic mice. We 
hypothesize that Sirt3 mediates the neuroprotection of 
ketones in ApoE4 transgenic mice. In this study, 9-
month-old human ApoE3 and ApoE4 transgenic mice 
were treated with either ketones or normal saline by 
daily subcutaneous injections for 3 months. We 
assessed learning and memory abilities, followed by 
measuring levels of Sirt3, synaptic proteins, the NAD+/ 
NADH ratio, and ATP production in the hippocampus 




Ketones improved learning and memory abilities of 
ApoE 4 mice 
 
After 3-month treatment of ketones or normal saline, all 
mice were tested for their learning and memory abilities 
in the Morris water maze. The escape latency measures 
how fast the mouse can find the platform to escape out 
of the water maze. In saline treatment groups, the 
escape latency of ApoE 4 mice was longer than that of 
ApoE 3 after two days of training (p< 0.05, Figure 1A). 
There was no difference in swimming speed (Figure 
1B). Ketone treatment improved the escaped latency in 
ApoE4 mice compared to ApoE4 mice receiving normal 
saline treatment (p< 0.05, Figure 1A). Ketones however 
didn’t improve the swimming speed (Figure 1B). 
Similar results were found in the probe test after four 
days of training. ApoE4 mice who received normal 
saline had the shortest duration and the least frequency 
in the target quadrant; while ApoE4 mice who received 
ketone treatment had the longest duration and the most 
frequency in the target quadrant (Figure 1D, 1E). This 
data indicated that ApoE4 mice had learning and 
memory impairment compared to ApoE3 mice. Ketone 
treatment improved learning and memory abilities of 
ApoE4 mice.  
 
Ketones increased the NAD+/ NADH ratio and ATP 
levels in ApoE 4 mice 
 
Since Sirt3 is NAD+-dependent, we tested the effect of 
ketones on NAD+/ NADH ratio in mouse fresh 
hippocampal and cortical tissues. After ketone 
treatment, the NAD+/NADH ratio was significantly 
increased in the hippocampus (ApoE3-NS: 4.1±0.1 vs. 
ApoE3-Ket: 8.8±0.2; ApoE4-NS: 3.1±0.2 vs. ApoE4-
Ket: 8.5±0.2; NS vs. Ket, p<0.01, Figure 2A) and the 
cortex (ApoE3-NS: 5.4±0.1 vs. ApoE3-Ket: 10.4±0.6; 
ApoE4-NS: 3.2±0.1 vs. ApoE4-Ket: 9.6±0.2; NS vs. 
Ket, p<0.01, Figure 2B) in both ApoE3 and ApoE4 
mice. We further measured ATP levels to evaluate the 
energy metabolism. Similar results were found on  
the change in ATP levels after ketone treatment in the 
hippocampus (ApoE3-NS: 49533±1239 vs. ApoE3-Ket: 
53688±1990; ApoE4-NS: 43541±1902 vs. ApoE4-Ket: 
47946±2177; NS vs. Ket, p<0.05, Figure 2C) and the 
cortex (ApoE3-NS: 58923±1663 vs. ApoE3-Ket: 
67486±1846; ApoE4-NS: 45902±880.4 vs. ApoE4-Ket: 
66935±3322; NS vs. Ket, p<0.01, Figure 2D) in both 
ApoE3 and ApoE4 mice. 
 
Ketones upregulated Sirt3, PSD95 and 
Synaptophysin in ApoE 4 mice 
 
Since synaptic integrity is critical for normal learning 
and memory ability, we measured the levels of post-
synaptic density protein 95 (PSD95), major synaptic 
vesicle protein (Synaptophysin) and Sirt3 in the 
hippocampus and the cortex after 3 months of ketone 
treatment. The treatment increased Sirt3, PSD95 and 
Synaptophysin levels in ApoE4 mice but not in 
ApoE3 mice. In the hippocampus (Figure 3A-D), 
Sirt3 levels (vs. Actin) were 23.7±2.0 (ApoE3-NS), 
26.8±2.0 (ApoE3-Ket), 16.6±0.9 (ApoE4-NS), and 
24.5±1.8 (ApoE4-Ket); PSD95 levels (vs. Actin) were 
104.3±5.2 (ApoE3-NS), 111.0±4.4 (ApoE3-Ket), 
86.3±4.0 (ApoE4-NS), and 104.1±4.3 (ApoE4-Ket) 
and Synaptophysin levels (vs. Actin) were 77.7±4.3 
(ApoE3-NS), 87.3±4.9 (ApoE3-Ket), 60.5±3.6 
(ApoE4-NS), and 76.7±4.2 (ApoE4-Ket). Similarly in 
the cortex (Figure 3E-H), Sirt3 levels (vs. Actin) were 
19.8±1.8 (ApoE3-NS), 20.2±1.2 (ApoE3-Ket), 
13.1±1.3 (ApoE4-NS), and 19.4±1.7 (ApoE4-Ket); 
PSD95 levels (vs. Actin) were 136.5±7.3 (ApoE3-
NS), 142.8±7.4 (ApoE3-Ket), 107.2±6.8 (ApoE4-NS), 
and 139.8±7.7 (ApoE4-Ket) and Synaptophysin levels 
(vs. Actin) were 117.8±7.4 (ApoE3-NS), 118.2±7.6 
(ApoE3-Ket), 85.6±6.0 (ApoE4-NS), and 114.7±7.3 
(ApoE4-Ket).
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Figure 1. Ketones improve learning and memory abilities of ApoE 4 mice. ApoE4 and ApoE3 mice were randomly divided into 
ketone treatment (Ket) or normal saline (NS) groups. After three months of treatment, all mice were tested in the Morris water maze. (A) 
Escape latency (s); (B) Velocity (cm/s); (C) Duration in the target quadrant (s); (D) Frequency in the target quadrant. N= 10–11 per group, 




Figure 2. Ketones increase the NAD+/ NADH ratio and ATP levels in ApoE 4 mice. ApoE4 and ApoE3 mice were treated with either 
ketones or normal saline for three months. Fresh hippocampal and cortical tissues were collected to measure NAD, NADH and ATP levels. (A) 
the NAD+/ NADH ratio in the hippocampus; (B) the NAD+/ NADH ratio in the cortex; (C) ATP levels in the hippocampus; (D) ATP levels in the 
cortex. N= 6–8 per group, # p<0.05, ApoE3-NS vs. ApoE4-NS. * p<0.05, ** p<0.01, ApoE3-NS vs. ApoE3-Ket, ApoE4-NS vs. ApoE4-Ket.  
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DISCUSSION 
 
In this study, our data showed that ketones enhanced the 
NAD+/ NADH ratio to increase Sirt3 expression, this 
led to improved ATP production, better synaptic 
integrity and finally improved the learning and memory 
ability of ApoE4 mice. Consistent with previous 
studies, our data suggest that Sirt3 mediates the 
neuroprotective effects of ketones by increasing 
neuronal energy metabolism in ApoE4 transgenic mice.  
 
Literature has shown that regional cerebral glucose 
hypometabolism plays a key role in AD pathogenesis 
and is correlated with the disease severity [23, 24]. 
Cerebral hypometabolism is one of the early signs of 
AD and is thought to be a predictor of disease 
progression [1–3]. ApoE4 is the major genetic risk 
factor of AD. Studies also find that ApoE4 is associated 
with reduced ATP levels in the cerebral cortex in mouse 
models [12–15]. Our previous studies showed that Sirt3 
played a critical role in the pathological change of AD 
and was significantly reduced by Aβ in our in vitro and 
in vivo experiments [17, 18]. The Sirt3-related energy 
pathway is involved in neuronal hypometabolism [18]. 
Sirt3 is NAD+-dependent. It is critical for ATP 
production in mitochondria. Knocking down Sirt3 
reduces ATP production while overexpressing Sirt3 
increases it [18].  Ketones, by enhancing the NAD+/ 
NADH ratio, regulate Sirt3 which in turn improves ATP 
production in mitochondria. Particularly in ApoE4 
mice, ketone treatment enhances the levels of NAD+, 
ATP, Sirt3 and synaptic proteins. This preservation in 
synaptic integrity translates into the improvement in 
learning and memory abilities. This suggests Sirt3 in 
addition to improvement in mitochondrial energy may 
also serve to protect synapses.  
 
Ketones can serve as an important energy substrate 
under starvation. Its routine use has been suggested to 
help professional athletes to improve their performance, 
but how ketones regulate the metabolism of skeletal and 
cardiac muscles during exercise of varying intensity and 
duration remains unknown [25, 26]. Our data didn’t 
show a change in swimming speed in any of the groups, 
with or without treatment. But we only tested them for a 
short period of time. A more detailed study with various 
time and exercise intensity will be warranted.  
 
In summary, we have shown that ketones protect 




Figure 3. Ketones upregulate Sirt3, PSD95 and Synaptophysin in ApoE 4 mice. ApoE4 and ApoE3 mice were treated with either 
ketones or normal saline for three months. Fresh hippocampal and cortical tissues were collected and homogenized for western blot. (A–D) 
Proteins levels were measured in the hippocampus: (A) Representative western blot bands for Sirt3, PSD95, Synaptophysin, and Actin were 
shown. (B) Sirt3, (C) PSD95 and (D) Synaptophysin levels were normalized with Actin. (E–H) Proteins levels were measured in the cortex: (E) 
Representative western blot bands for Sirt3, PSD95, Synaptophysin and Actin were shown. (F) Sirt3, (G) PSD95 and (H) Synaptophysin levels 
were normalized with Actin. N=8 per group, # p<0.05, ApoE3-NS vs. ApoE4-NS; * p<0.05, ApoE4-NS vs. ApoE4-Ket.  
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Sirt3 regulation. This will shed lights on the 




ApoE 4 and ApoE 3 transgenic mice 
 
Transgenic mice carrying either human ApoE4 or 
ApoE3 allele were purchased from Taconic 
Biosciences (Rensselaer, NY). These transgenic lines 
have been shown to transcribe and express appropriate 
human ApoE3 and ApoE4 protein in the brain, the 
liver, and other tissues without contamination of the 
endogenous mouse ApoE gene. We used 9-month-old 
homozygous mice (littermates) for our experiments. 
ApoE3 mice and ApoE4 (10-11 animals/ group) were 
treated with ketones or control saline by daily 
subcutaneous injections from 9 months of age 
(ketones, beta-hydroxybutyrate (BHB): 600 
mg/kg/day; acetoacetate (ACA): 600 mg/kg/day; 
ACA: 150 mg/kg/day). All mice were labeled with 
serial numbers and were blinded to the person who 
tested their behavior or Western blot etc. After 
behavioral tests, animals were euthanized. The brain 
was processed for further analysis.  
 
All mice were housed in a temperature and humidity-
controlled vivarium, kept on a 12-hour dark/light cycle, 
and had free access to food and water. All experimental 
procedures were approved by the Institutional Animal 
Care and Use Committee of the Barrow Neurological 
Institute and performed according to the Revised Guide 
for the Care and Use of Laboratory Animals.  
 
Morris water maze  
 
Spatial learning was assessed by the Morris Water Maze 
(MWM) task adapted for mice [16]. Briefly, each 
mouse was introduced into the circular pool and 
allowed to swim. The time (escape latency) required to 
reach the platform located in northeast quadrant, as well 
as the swimming speed was recorded in each trial. Once 
the mouse located the platform, it was permitted to 
remain on it for 10 seconds. If the mouse did not locate 
the platform within 120 seconds, it was placed on the 
platform for 10 seconds. The mouse was given four 
trials per day for 4 days with an inter-trial interval of 20 
minutes. Each trial was initiated by randomly placing an 
animal in one of the four starting locations. Escape 
latency and swimming speed were collected and 
analyzed using EthoVision® 3.1 tracking software 
(Noldus Information Technology Inc., Leesburg, VA). 
On the 5th day, a single probe trial was carried out. In 
this trial, the platform was removed and each mouse 
was placed from southwest quadrant of the pool and 
allowed to swim for 120 seconds. The time spent in the 
target quadrant (northeast) was collected and calculated 
using EthoVision® 3.1 tracking software.  
 
Brain tissue collection 
 
After 3-month treatment, mice were placed in a chamber 
with 5% isoflurane for 5 min, and decapitated when fully 
sedated. Fresh brain tissues (hippocampus and temporal 
cortex) were isolated and collected immediately on ice. 
For western blot, brain tissues (hippocampus and cortex) 
were homogenized and sonicated with ice-old RIPA 
buffer (#9806, Cell Signaling, Danvers, MA) with 
protease inhibitor cocktail (#p8340, Sigma-Aldrich, 
St.Louis, MO) on ice. Total proteins were collected after 
centrifugation at 4°C (19000g, 20mins) and saved in  
−80°C for western blot.  For ATP and NAD+/NADH 
measurements, fresh temporal brain tissues were 
collected. ATP levels, total NAD+ and NADH were 
tested according to the assay protocols. 
 
Western blot  
 
Fifty µg total proteins were used for western blotting. 
Primary antibodies were the following: anti-Sirt3 
(#5490S, Cell Signaling Technology Inc., Danvers, 
MA), anti-postsynaptic density protein 95 (PSD-95, 
#3450, Cell Signaling Technology Inc.), anti-
synaptophysin (#12270, Cell Signaling Technology 
Inc.), anti-β-actin (Santa Cruz, Dallas, TX), IRDye 
800CW and IRDye 680CW antibodies (LI-COR 
Biosciences, Lincoln, NE). Immunoreactivity signals 
were quantified using Odyssey CLx. Protein levels were 





Fresh mouse temporal brain tissue (20 mg) was 
collected and homogenized in 200 ul 2M perchloric acid 
on ice. Samples were kept on ice for 30 minutes. After 
the samples were centrifuged, the supernatant was 
collected and diluted the volume to 1000ul with ATP 
assay buffer. Then, the supernatant was transferred into 
two new 500ul tubes. Supernatant were neutralized to a 
pH between 7.0 and 7.6, and excess perchloric acid was 
precipitated with ice-cold potassium hydroxide (2M). 
After repeating the neutralization and centrifugation 
process, new supernatant was collected for ATP assay. 
ATP levels were tested using a Luminescent ATP 
detection assay kit (#ab83355, Abcam, Cambridge, 
MA) according to the manufacturer’s protocol.  
 
NAD+ and NADH measurements  
 
Fresh mouse temporal brain tissue (20 mg) was 
collected and homogenized in 400ul NAD+/ NADH 
www.aging-us.com 4584 AGING 
extract buffer on ice. After the samples were 
centrifuged, the supernatant was collected into a new 
tube and deproteinized with perchloric acid (4M). After 
a second centrifuge and second supernatant was 
transferred into a new tube, the supernatant was 
neutralized to a pH between 7.0 and 7.6 with ice-cold 
potassium hydroxide (2M). Then, the samples were 
centrifuged and the supernatant was collected for total 
NAD+ and NADH assay. Total NAD+ and NADH were 
tested using an NAD+/NADH assay kit (#ab65348, 
Abcam) according to the manufacturer’s protocol. 
NAD+/NADH ratio was calculated based on the value 





We applied ANOVA with post-hoc Tukey’s test to 
compare values across multiple groups by using 
GraphPad Prism version 7.03 and Pearson’s correlation 
analysis for correlation analyses by using IBM SPSS 
statistics version 23. Statistical significance was set at 
p< 0.05. 
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